Christopher Van Tuyl - Dec 16, 2024 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Signature
/s/ Eva Renee Barnett, attorney-in-fact for Christopher Van Tuyl
Stock symbol
IMVT
Transactions as of
Dec 16, 2024
Transactions value $
$0
Form type
4
Date filed
12/18/2024, 05:02 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMVT Common Stock Award $0 +110K $0.00 110K Dec 16, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMVT Stock Option (right to buy) Award $0 +137K $0.00 137K Dec 16, 2024 Common Stock 137K $27.63 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the units on December 16, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.
F2 This option was granted pursuant to the Issuer's 2019 Equity Incentive Plan. The shares underlying the option will vest as to 25% of the shares on December 16, 2025, and the remainder will vest in 12 successive substantially equal quarterly installments over three years thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.